These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21109709)

  • 1. [Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules].
    Tabaczar S; Koceva-Chyła A; Matczak K; Gwoździński K
    Postepy Hig Med Dosw (Online); 2010 Nov; 64():568-81. PubMed ID: 21109709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
    Wang R; Wang H; Wang Z
    J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transduction pathways of taxanes-induced apoptosis.
    Ganansia-Leymarie V; Bischoff P; Bergerat JP; Holl V
    Curr Med Chem Anticancer Agents; 2003 Jul; 3(4):291-306. PubMed ID: 12769774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies on biological activity of certain microtubule-interacting taxanes.
    Miglietta A; Bocca C; Gabriel L
    Chem Biol Interact; 2002 Mar; 139(3):283-99. PubMed ID: 11879817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
    Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
    Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of inhibition of endothelial cell migration by taxanes.
    Kamath K; Smiyun G; Wilson L; Jordan MA
    Cytoskeleton (Hoboken); 2014 Jan; 71(1):46-60. PubMed ID: 24155271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
    Zhu L; Zhang C; Lü X; Song C; Wang C; Zhang M; Xie Y; Schaefer HF
    J Mol Model; 2020 May; 26(6):162. PubMed ID: 32474655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
    Edler MC; Buey RM; Gussio R; Marcus AI; Vanderwal CD; Sorensen EJ; Díaz JF; Giannakakou P; Hamel E
    Biochemistry; 2005 Aug; 44(34):11525-38. PubMed ID: 16114889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action.
    Abal M; Andreu JM; Barasoain I
    Curr Cancer Drug Targets; 2003 Jun; 3(3):193-203. PubMed ID: 12769688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of antitumor activity of taxanes in lung cancer (Review).
    Zhao J; Kim JE; Reed E; Li QQ
    Int J Oncol; 2005 Jul; 27(1):247-56. PubMed ID: 15942666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microtubules and antineoplastic drugs].
    Arioka H; Saijo N
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.